Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

BioCentury This Week

English - June 14, 2024 00:00 - 26 minutes - 18.1 MB - ★★★★★ - 11 ratings
Science biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

Next Episode: Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS

BIO’s annual meeting took place amid heightened industry concerns regarding the Biosecure Act, which took yet another unexpected turn this week. On a special edition of the BioCentury This Week recapping the meeting, BioCentury's editors discuss the latest on the anti-China biopharma legislation, including misperceptions of what the bill seeks to accomplish.
Special guest Chris Cargill, the CEO of Nxera Pharma, joins the podcast to discuss the expanded APAC presence at this year’s BIO; Japan’s push to build the biotech ecosystem in the country; and how Nxera (formerly Sosei) is evolving. And finally, BioCentury’s editors deliver the takeaways from Karen Tkach Tuzman’s BIO panel focused on radiopharmaceuticals, including debate on the merits of long- versus short-lived radioisotopes. This week’s podcast is sponsored by Nxera Pharma.

View full story: https://www.biocentury.com/article/652686

00:01 - Sponsor Message: Nxera Pharma
02:34 - BIO Wrap: Biosecure
09:12 - Japan & Nxera
18:52 - Radiopharma